The Global Orphan Drugs Market is estimated to be US$ 869.6 million by 2030 with a CAGR of 10.4% during the forecast period. Orphan drugs are the pharmaceutical mediators which are developed to treat rare medical conditions. Orphan drugs would not be able to earn profit because the orphan drugs are used to treat the rare diseases. It can only produce profit by the involvement of government assistant. Orphan drugs use to diagnoses and to prevent the diseases. Orphan drugs are not developed in industry, but it is generated for the public welfare.
Key Highlights:
·
In present
scenario, there are several countries and organizations, which have defined
“orphan” and “rare” diseases. The prevalence rate for each definition varies
from organization to organization, and country to country. While, several
developed markets have specific definition for such diseases and treatments,
there are however, many countries in the emerging markets, which lack the
proper definitions and guidelines, along with lack of proper guidance from the
medical community and concerned authorities toward the orphan diseases. This is
among the major challenges and restraints for growth of orphan medication,
across a large part of the world.
·
In August
2019, Janssen and AbbVie received the European Commission (EC) approval of
imbruvica (ibrutinib) for expanded use in two indications. The regulator has
approved expanding the scope of the drug to include its use in combination with
obinutuzumab in adults with previously untreated chronic lymphocytic leukemia
(CLL), and for the treatment of adults with Waldenström's macroglobulinemia
(WM) in combination with rituximab.
Analyst View:
In present scenario, there are several countries and
organizations, which have defined “orphan” and “rare” diseases. The prevalence
rate for each definition varies from organization to organization, and country
to country. While, several developed markets have specific definition for such
diseases and treatments, there are however, many countries in the emerging
markets, which lack the proper definitions and guidelines, along with lack of
proper guidance from the medical community and concerned authorities toward the
orphan diseases. This is among the major challenges and restraints for growth
of orphan medication, across a large part of the world.
Browse 60 market data tables* and 35 figures* through
140 slides and in-depth TOC on “Global Orphan Drugs Market, By Drug Type
(Biological and Non- Biological), By Top Selling Drugs (Revlimid, Rituxan,
Copaxone, Opdivo, Keytruda, Imbruvica, Avonex, Sensipar, Soliris, and Other Top
Selling Drugs), By Disease Type (Oncology, Hematology, Neurology,
Cardiovascular, and Other Disease Types), By Phase (Phase I, Phase II, Phase
III, and Phase IV), and By Region (North America, Europe, Asia Pacific, Latin
America, and Middle East & Africa) - Trends, Analysis and Forecast till
2030”
To know the upcoming trends and insights prevalent in this
market, click the link below:
https://www.prophecymarketinsights.com/market_insight/Global-Orphan-Drugs-Market-By-3793
Key Market Insights from the report:
The Global Orphan Drugs Market is estimated to be US$ 869.6
million by 2030 with a CAGR of 10.4% during the forecast period. The global orphan drugs market is segmented based on drug
type, disease, disease type, phase, and region.
·
On the basis
of drug type, the global orphan drugs market is segmented into biological and
non- biological.
·
On the basis of top selling
drugs, the target market is segmented into revlimid, rituxan, copaxone, opdivo,
keytruda, imbruvica, avonex, sensipar, soliris, and other top selling drugs.
·
ased on disease type, the
global market is classified into oncology, hematology, neurology,
cardiovascular, and other disease types.
·
On the basis of phase segment,
the target market divided into phase I, phase II, phase III, and phase IV.
·
Based on region the global
orphan drugs market is segmented into North America, Europe, Asia Pacific,
Latin America, and Middle East & Africa. The global market in North America
region is seen to have a matured growth since this market correlates with the
increasing growth rate of orphan disease.
Competitive Landscape:
The key players operating the global orphan drugs market
involves AbbVie Inc., Celgene Corporation, Biogen, Teva Pharmaceutical
Industries, F. Hoffmann-La Roche AG, Bristol-Myers Squibb Company, Alexion
Pharmaceuticals, Amgen, Merck & Co. Inc., Jazz Pharmaceuticals Prominent
players operating in the target market are focusing on the strategic
partnerships as well as launching of the drug types in order to gain
competitive edge in the target market.
The market provides detailed information regarding the
industrial base, productivity, strengths, manufacturers, and recent trends
which will help companies enlarge the businesses and promote financial growth.
Furthermore, the report exhibits dynamic factors including segments,
sub-segments, regional marketplaces, competition, dominant key players, and
market forecasts. In addition, the market includes recent collaborations,
mergers, acquisitions, and partnerships along with regulatory frameworks across
different regions impacting the market trajectory. Recent technological
advances and innovations influencing the global market are included in the
report.
About Prophecy Market Insights
Prophecy Market Insights is specialized market research,
analytics, marketing/business strategy, and solutions that offers strategic and
tactical support to clients for making well-informed business decisions and to
identify and achieve high-value opportunities in the target business area. We
also help our clients to address business challenges and provide the best
possible solutions to overcome them and transform their business.
Some Important Points Answered in this Market Report Are
Given Below:
·
Explains an
overview of the product portfolio, including product development, planning, and
positioning
·
Explains
details about key operational strategies with a focus on R&D strategies,
corporate structure, localization strategies, production capabilities, and financial
performance of various companies.
·
Detailed
analysis of the market revenue over the forecasted period.
·
Examining
various outlooks of the market with the help of Porter’s five forces analysis,
PEST & SWOT Analysis.
·
Study on the
segments that are anticipated to dominate the market.
·
Study on the
regional analysis that is expected to register the highest growth over the
forecast period
Key Topics Covered
1. Introduction
·
Study
Deliverables
·
Study
Assumptions
·
Scope of the
Study
2. Research Methodology
3. Executive Summary
·
Opportunity
Map Analysis
·
Market at
Glance
·
Market Share
(%) and BPS Analysis, by Region
·
Competitive
Landscape
·
Heat Map
Analysis
·
Market
Presence and Specificity Analysis
4. Investment Analysis
5. Competitive Analysis
To know more
Contact Us:
Sales
Prophecy Market Insights
No comments:
Post a Comment